Loading stock data…
$6.18-0.01 (-0.24%)
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally.
Embecta Corp. in the Healthcare sector is trading at $6.18 with a market capitalization of $277M. Wall Street consensus targets $4.00 (2 analysts), implying a -35.3% move over the next 12 months. The stock is currently 59% below its 52-week high of $14.91, remaining 8.0% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $271.70M↑ | $221.80M↓ | $261.20M↓ | $264.00M↓ | $295.50M |
| Gross Profit | $153.30M↑ | $127.80M↓ | $161.70M↑ | $158.50M↓ | $197.10M |
| Operating Income | $64.30M↑ | $42.90M↓ | $76.30M↑ | $64.30M↓ | $105.00M |
| Net Income | $21.10M↑ | -$4.10M↓ | $44.10M↑ | $26.40M↓ | $45.50M |
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection device...